ep impact one-tim non-cash warranti
charg lower report share count
versu estim
recent spent time road manag confid talk
mani opportun ahead led pipelin basal-iq begin roll
august control-iq expect highlight
new platform provid new tailwind core busi
increment driver two still new opportun convert former anima
patient exit market captur increas pump renew
bump estim higher assum new patient
add led increas anima patient convers assumpt continu
see intern estim launch begin conserv
renew durabl insulin pump four-year warranti life patient often
stretch pump beyond four year model take account pump place
year prior sale first begin ramp meaning
replac cycl build contribut estim
sale forecast replac revenu
exit follow announc exit insulin pump busi support
anima pump ceas septemb us instal
base model assum earli captur anima patient build
new product flow estim increment
sale
pipelin recent approv basal-iq begin roll-out
august control-iq hybrid-clos loop approv remain target
manag highlight flexibl system look ahead
uniqu softwar updat built slim icgm design
allow meaning quicker regulatori pathway connect
advanc sensor
note remain confid reach gross margin exit
volum ramp new higher volum manufactur facil
run manag highlight new ou distributor motiv
follow exit distributor ex-anima experienc
distributor posit well believ ou launch begin
sale estim rise
increas anima convers assumpt led new product
offer continu view initi ou estim conserv
higher sale estim medium-term anima sale assumpt pt
rise
inc medic
devic compani user-centr
design
develop commerci
patient
analyst certif import disclosur see disclosur
underli pump volum growth mid-teen
anima patient remain higher level new patient mix near-
increas captur potenti replac patient reach
sever new opportun includ exit
larg competitor anima ramp replac cycl
pipelin next-gener sensor-aug pump
plan intern expans begin also well
underway balanc sheet posit recent improv
investor focu increasingli shift opportun
launch basal iq system august
roll fda submiss control iq system
approv control iq
quicker acceler new pump growth base sensor-
greater expect contribut anima
greater expect competit pressur particularli
failur reach gross margin long-term thu longer
expect move cash flow break-even
target price impli ev/sal rais versu previous take account higher medium-term estim
well target multipl in-lin forward multipl high-growth med-tech peer intern estim
conserv end point
competit new product rollout regulatori approv gross margin/opex leverag requir reach cash flow break-even
interest incom
sourc oppenheim estim compani report
